<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293968</url>
  </required_header>
  <id_info>
    <org_study_id>qums353</org_study_id>
    <nct_id>NCT01293968</nct_id>
  </id_info>
  <brief_title>Therapeutic Effects of &quot;Ibuprofen, Diphenhydramine and Aluminium MgS&quot; on Recurrent Aphthous Stomatitis</brief_title>
  <official_title>Therapeutic Effects of &quot;Ibuprofen, Diphenhydramine and Aluminium MgS&quot; on Recurrent Aphthous Stomatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qazvin University Of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qazvin University Of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intention of the study is to study the effects of Ibuprofen, Diphenhydramine and
      Aluminium MgS in decreasing the signs of recurrent aphthous stomatitis (RAS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent aphthous stomatitis (RAS) is the most painful oral lesion with a considerable
      prevalence . The most common aphthous ulcer treatments include applying topical agents such
      as antibiotics, Non Steroidal Anti Inflammatory Drugs (NSAIDs) to immunosuppressants.

      The mixture of Diphenhydramine and Aluminum MgS suspension has been prescribed as an
      analgesic mouthwash for a long time in order to decrease a great number of oral ulcers
      symptoms such as aphthous ulcers. Ibuprofen is a potent NSAID with fair anti-inflammatory
      potential prescribed in dental pains.

      This double-blind randomized clinical trial was conducted to assess the effect of Ibuprofen,
      Diphenhydramine and Aluminium MgS mixture on symptoms of aphthous ulcers.40 patients will be
      participating in this study,20 will receive the mixture of Diphenhydramine and Aluminium MgS
      while the other group will receive Ibuprofen, Diphenhydramine and Aluminium MgS mixture.

      All patients will be instructed to apply the drug on the site of the ulcer 30-60 minutes
      before meals, 3 times daily. The ulcers will be assessed when the drug is applied for 3 days
      and the level of pain and irritation will be estimated by VAS (Visual Analogue Scale, a
      scaled ruler which the zero point displays the zone of lack of pain and the 10th point was
      considered as the zone of maximum pain).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation</measure>
    <time_frame>four days after the start of the study</time_frame>
    <description>pain sensation was measured by VAS (Visual Analogue Scale, a scaled ruler which the zero point displays the zone of lack of pain and the 10th point was considered as the zone of maximum pain)) 4 days after the consumption of the solution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of Ibuprofen, Diphenhydramine, Aluminium MgS and Diphenhydramine and Aluminium MgS in Decreasing the Pain Level and Burning Sensation</measure>
    <time_frame>4 days after the solution consumption</time_frame>
    <description>pain sensation was measured by VAS (Visual Analogue Scale) 4 days after the consumption of the solutions and the results of both drugs was analyzed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Aphthous Stomatitis</condition>
  <arm_group>
    <arm_group_label>5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen, Diphenhydramine and Aluminium MgS</intervention_name>
    <description>3 times daily for 3 days</description>
    <arm_group_label>5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine and Aluminium MgS</intervention_name>
    <description>3 times daily for 3 days</description>
    <arm_group_label>100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  possessing at least one painful aphthous ulcer in the last 3 days

          -  older than 10 years of age

        Exclusion Criteria:

          -  systemic disease or specific syndrome (such as Behcet's)

          -  pregnancy

          -  breastfeeding

          -  allergy to NSAIDs

          -  history of asthma, peptic ulcers, hepatic and renal failures and hemorrhagic disorders

          -  consumption of anti-inflammatory medications in the last 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katayun Borhanmojabi, D.D.S,M.S</last_name>
    <role>Study Chair</role>
    <affiliation>QUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katayun Borhanmojabi, D.D.S,M.S</last_name>
    <role>Study Director</role>
    <affiliation>QUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjan Nasiri asl, PhD</last_name>
    <role>Study Director</role>
    <affiliation>QUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faeze Mirmiran, D.D.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>QUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pantea Nazeman, student</last_name>
    <role>Principal Investigator</role>
    <affiliation>QUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dental faculty of Qazvin University of Medical Sciences</name>
      <address>
        <city>Qazvin</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qazvin University of Medical sciences</name>
      <address>
        <city>Qazvin</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <results_first_submitted>May 5, 2011</results_first_submitted>
  <results_first_submitted_qc>May 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2012</results_first_posted>
  <last_update_submitted>May 16, 2012</last_update_submitted>
  <last_update_submitted_qc>May 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qazvin University Of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Pantea Nazeman</investigator_full_name>
    <investigator_title>Miss</investigator_title>
  </responsible_party>
  <keyword>Aphthous Stomatitis</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>treatment efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Stomatitis, Aphthous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen, Diphenhydramine and Aluminium MgS</title>
        </group>
        <group group_id="P2">
          <title>Diphenhydramine and Aluminium MgS</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-cooperation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibuprofen, Diphenhydramine and Aluminium MgS</title>
        </group>
        <group group_id="B2">
          <title>Diphenhydramine and Aluminium MgS</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="10.04"/>
                    <measurement group_id="B2" value="32.0" spread="10.0"/>
                    <measurement group_id="B3" value="32.2" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation</title>
        <description>pain sensation was measured by VAS (Visual Analogue Scale, a scaled ruler which the zero point displays the zone of lack of pain and the 10th point was considered as the zone of maximum pain)) 4 days after the consumption of the solution</description>
        <time_frame>four days after the start of the study</time_frame>
        <population>The intention of the study is to study the effects of Ibuprofen, Diphenhydramine and Aluminium MgS in decreasing the signs of RAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen, Diphenhydramine and Aluminium MgS</title>
            <description>the group received the study solution containing 5cc ibuprofen 100mg, 10 cc Diphenhydramine 25 mg and 10 cc AlMgS which was applied on the ulcers 30-60 minutes before meals, 3 times daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Aluminium MgS</title>
            <description>the group received the placebo solution containing 10 cc Diphenhydramine 25 mg and 10 cc AlMgS which was applied on the ulcers 30-60 minutes before meals, 3 times daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation</title>
          <description>pain sensation was measured by VAS (Visual Analogue Scale, a scaled ruler which the zero point displays the zone of lack of pain and the 10th point was considered as the zone of maximum pain)) 4 days after the consumption of the solution</description>
          <population>The intention of the study is to study the effects of Ibuprofen, Diphenhydramine and Aluminium MgS in decreasing the signs of RAS</population>
          <units>scores in Visual Analogue Scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.176" lower_limit="1.169" upper_limit="5.183"/>
                    <measurement group_id="O2" value="3.821" lower_limit="2.028" upper_limit="5.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Ibuprofen, Diphenhydramine, Aluminium MgS and Diphenhydramine and Aluminium MgS in Decreasing the Pain Level and Burning Sensation</title>
        <description>pain sensation was measured by VAS (Visual Analogue Scale) 4 days after the consumption of the solutions and the results of both drugs was analyzed</description>
        <time_frame>4 days after the solution consumption</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ibuprofen, Diphenhydramine and Aluminium MgS</title>
        </group>
        <group group_id="E2">
          <title>Diphenhydramine and Aluminium MgS</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of population. Studying just one concentration of Ibuprofen. Lack of a placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Katayun Borhanmojabi</name_or_title>
      <organization>Qazvin University of Medical Sciences</organization>
      <phone>09127841440</phone>
      <email>ka.mojabi@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

